Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

If you are located in the EEAEuropean Economic Area, the United Kingdom, or Switzerland, you can change your settings at any time by clicking Manage Cookies in the footer of our website.

Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

ViaFect™ Transfection Reagent

E4981_ViaFect--Transfection-Reagent--0-75ml_3
customize-this-small

Best Transfection Performance Across Many Cell Lines

  • Performs better than or equal to other best-in-class transfection reagents
  • Simple transfection protocol with minimal optimization required
  • Low toxicity for routine and challenging cell lines

Size

Catalog number selected: E4981

Please Enquire
This product is discontinued
Request a Sample
Not available in all countries
This product is available under our Early Access program - Learn More
This product is available under our Catalog (FT) program - Learn More
ViaFect™ Transfection Reagent
0.75ml
Your price:
Change Configuration

Develop More Biologically Relevant Assays. You Pick the Cell Line.

Cell biology is critical to transfection-based experiments. Not only do the cells need to maintain their viability and metabolism through the transfection process, they also must accurately represent the biology being modeled in the experiment. ViaFect™ Transfection Reagent allows high-efficiency transfection of a wide range of cell types without compromising cell viability, and provides an easy-to-use protocol that gives superior performance with minimal optimization. Now you can design the right assay in the right cells to model the biology you are studying.

Excellent Performance Compared With Other Best-in Class Transfection Reagents


Promega offers 3 premium transfection reagents, FuGENE® 6, FuGENE® HD and ViaFect. All offer broad-spectrum transfection capability and low toxicity. We performed transfection experiments with FuGENE® 6, FuGENE® HD, ViaFect and Lipofectamine (ThermoFisher Scientific). Although each reagent clearly worked best on certain cell lines, and none were perfect for every cell line, ViaFect™ Transfection Reagent yielded equal or greater luciferase expression over a wider variety of cell lines than any of the other reagents tested.


Full details of these transfection experiments are available in the article below:

Download Article
Cell Line ViaFect FuGENE® 6 FuGENE® HD Lipofectamine® 2000 Compare ViaFect,
FuGENE,
Lipofectamine® 2000		 Compare ViaFect,
Lipofectamine® 3000
A549 +++ ++ +++ See Data See Data
C2C12 +++ See Data See Data
CHO +++ ++ ++ See Data
COS7 +++ +++ +++ +++ See Data
H9C2 +++ ++ See Data
HCT116 +++ +++ ++ See Data See Data
HEK293 +++ ++ See Data See Data
HeLa ++ +++ See Data
HepG2 +++ See Data See Data
HT-29 +++ +++ See Data
Jurkat +++ ++ See Data See Data
K562 +++ See Data See Data
LNCaP +++ See Data
MCF7 +++ +++ See Data See Data
NIH-3T3 ++ +++ See Data
PC-12 +++ ++ +++ See Data
PC-3 +++ +++ See Data See Data
RAW 264.7 +++ +++ ++ See Data
U2OS +++ ++ See Data See Data
Key +++ = >80% of maximum RLU (Relative Luminescence Units); ++ = 50–80% of maximum RLU
Each cell line was transfected with a luciferase reporter plasmid using either ViaFect™ Transfection Reagent, Lipofectamine® 2000 Transfection Reagent or Lipofectamine® 3000 Transfection Reagent following manufacturer instructions, applying either 5µl (50ng of DNA) or 10µl (100ng of DNA) of the transfection complex in each well of a 96-well plate. Luciferase expression (bars) and cell viability (lines) were measured either 24h post-transfection (Lipofectamine® 2000 comparison) or 24hr and 48hr post-transfection (Lipofectamine® 3000 comparison) using the ONE-Glo™ + Tox Luciferase Reporter and Cell Viability Assay.

Transfect the Cell Line of Your Choice

Design biologically relevant assays in workhorse adherent cell models, suspension cells important for studying cell signaling, and even differentiated cell lines derived from stem cells. ViaFect™ Transfection Reagent gives you the flexibility to do the research you need to do.

iCell hepatocytes transfected with viafect reagent 12642-W
iCell® Hepatocytes* 

iCell® Hepatocytes transfected with ViaFect™ Transfection Reagent and a GFP reporter plasmid at a 6:1 reagent:DNA ratio; GFP expression imaged one day post-transfection.
cardiomyocytes transfected with viafect reagent 12643-W
iCell® Cardiomyocytes*

iCell® Cardiomyocytes transfected with ViaFect™ Transfection Reagent and a GFP reporter plasmid at a 2:1 reagent:DNA ratio; GFP expression imaged one day post-transfection.
Neurons transfected with Viafect reagent 12644-W
iCell® DopaNeurons*

iCell® DopaNeurons transfected with ViaFect™ Transfection Reagent and a GFP reporter plasmid at a 4:1 reagent:DNA ratio; GFP expression imaged 3 days post-transfection.
*Experiments were performed using Cellular Dynamics iCell® human tissue cells plated into 96 well plates. Data courtesy of Cellular Dynamics International.

ViaFect™ Transfection Citations, Cell Line by Cell Line


ViaFect™ Transfection Reagent is gaining popularity as a high-performance, low-toxicity reagent that performs well across a wide range of cell lines. Expand the section below to see a list of 2018 and 2017 articles citing use of ViaFect in a variety of cell types. 

Expand to View Citations
Here are over 100 papers from 2017 and 2018 demonstrating use of ViaFect with many different cell types. Enter your cell line of interest in the Search field to see if it is represented in this collection.

Search citations

Cell Line Citation
A549 Somensi, N., et al. (2017) Extracellular HSP70 Activates ERK1/2, NF-kB and Pro-Inflammatory Gene Transcription Through Binding with RAGE in A549 Human Lung Cancer Cells. Cell. Physiol. Biochem. 42, 2507-22.
AF22 Chai, M., et al. (2018) Chromatin remodeler CHD7 regulates the stem cell identity of human neural progenitors. Genes Dev. 32, 165-80.
AGS Cerda-Opazo, P., et al. (2018) Inverse expression of survivin and reprimo correlates with poor patient prognosis in gastric cancer. Oncotarget 9, 12853-67.
AU565 Bagu, E.T., et al. (2017) Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation. Oncotarget 8, 11442-59.
B16F0 Morita, T. and Hayashi, K. (2018) Tumor progression is mediated by thymosin-β4 through a TGFβ/MRTF signaling axis. Mol. Cancer Res. 16, 880-93.
B16F1 Morita, T. and Hayashi, K. (2018) Tumor progression is mediated by thymosin-β4 through a TGFβ/MRTF signaling axis. Mol. Cancer Res. 16, 880-93.
BJ1-7TGP Kramer, N., et al. (2017) Autocrine WNT2 signaling in fibroblasts promotes colorectal cancer progression. Oncogene 36, 5460-72.
Bovine Aortic
Endothelial Cells		 Gupta, R.M., et al. (2017) A genetic variant associated with five vascular diseases is a distal regulator of endothelin-1 gene expression. Cell 170, 522-33.
BT Alkheraif, A.A., et al. (2017) Type 2 BVDV Npro suppresses IFN-1 pathway signaling in bovine cells and augments BRSV replication. Virology 507, 123-34.
C2C12 Saklayen, N., et al. (2017) Analysis of poration-induced changes in cells from laser-activated plasmonic substrates. Biomed. Opt. Express 8, 4756-71.
CHO Hoonakker, M.E., et al. (2017) Reporter cell lines for detection of pertussis toxin in acellular pertussis vaccines as a functional animal-free alternative to the in vivo histamine sensitization test. Vaccine 35, 1152-60.
COS-7 Nakagawa, T., et al. (2017) N-glycan-dependent cell-surface expression of the P2Y2 receptor and N-glycan-independent distribution to lipid rafts. Biochem. Biophys. Res. Comm. 485, 427-31.
COV-504 Lu, T., et al. (2018) Blockade of ONECUT2 expression in ovarian cancer inhibited tumor cell proliferation, migration, invasion and angiogenesis. Cancer Sci. 109, 2221-34.
EH-GB1 Ma, Q., et al. (2018) EMP3, which is regulated by miR-663a, suppresses gallbladder cancer progression via interference with the MAPK/ERK pathway. Cancer Lett. 430, 97-108.
EH-GB1 Hao, J., et al. (2017) Downregulation of BRD4 inhibits gallbladder cancer proliferation and metastasis and induces apoptosis via PI3K/AKT pathway. Int. J. Oncol. 51, 823-32
GBC-SD Ma, Q., et al. (2018) EMP3, which is regulated by miR-663a, suppresses gallbladder cancer progression via interference with the MAPK/ERK pathway. Cancer Lett. 430, 97-108.
GBC-SD Hao, J., et al. (2017) Downregulation of BRD4 inhibits gallbladder cancer proliferation and metastasis and induces apoptosis via PI3K/AKT pathway. Int. J. Oncol. 51, 823-33
GIST882 Wang, L., et al.(2017) Orai1 mediates tumor-promoting store-operated Ca2+ entry in human gastrointestinal stromal tumors via c-KIT and the extracellular signal–regulated kinase pathway. Tumor Biol. 39, 1010428317691426.
H1299 Eriksson, M., et al. (2017) The effect of mutant p53 proteins on glycolysis and mitochondrial metabolism. Mol. Cell. Biol. 37, e00328-17.
H358 Motooka, Y., et al. (2017) Pathobiology of Notch2 in lung cancer. Pathology 49, 486-93.
H5 Mouse chondrocytes Kalev-Zylinska, M.L., et al. (2018) Altered N-methyl D-aspartate receptor subunit expression causes changes to the circadian clock and cell phenotype in osteoarthritic chondrocytes. Osteoarthr. Cartilage https://doi.org/10.1016/j.joca.2018.06.015
H9c2 Mudaliar, H, et al. (2017) Remote ischemic preconditioning attenuates EGR-1 expression following myocardial ischemia reperfusion injury through activation of the JAK-STAT pathway. Int. J. Cardiol. 228, 729-41.
HCC Xu, S., et al. (2018) NFATc1 is a tumor suppressor in hepatocellular carcinoma and induces tumor cell apoptosis by activating the FasL-mediated extrinsic signaling pathway. Cancer Med. DOI: 10.1002/cam4.1716.
HCC1569 Onodera, Y., et al. (2018) Arf6-driven cell invasion is intrinsically linked to TRAK1-mediated mitochondrial anterograde trafficking to avoid oxidative catastrophe. Nat. Comm. 9, 2682.
HCC70 Bagu, E.T., et al. (2017) Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation. Oncotarget 8, 11442-59.
HCT 116 Kranz, P., et al. (2017) PDI is an essential redox-sensitive activator of PERK during the unfolded protein response (UPR).  Cell Death Dis. 8, e2986.
HCT 116 Lin, H., et al. (2017) DHX32 promotes angiogenesis in colorectal cancer through augmenting β-catenin signaling to induce expression of VEGFA. EBioMedicine 18, 62-72
HCT 116 Eriksson, M., et al. (2017) The effect of mutant p53 proteins on glycolysis and mitochondrial metabolism. Mol. Cell. Biol. 37, e00328-17.
HCT-8 Lin, H., et al. (2017) DHX32 promotes angiogenesis in colorectal cancer through augmenting β-catenin signaling to induce expression of VEGFA. EBioMedicine 18, 62-72
HEK 293 Higashioki, K., et al. (2017) Myogenic differentiation from MYOGENIN-mutated human iPS cells by CRISPR/Cas9. Stem Cells Intl. 9210494.
HEK 293T Foxler, D.E., et al. (2018) A HIF–LIMD1 negative feedback mechanism mitigates the pro‐tumorigenic effects of hypoxia. EMBO Mol. Med. 10, e8304
HEK 293T Zhang, Y., et al. (2017) Rescue of Pink1 deficiency by stress-dependent activation of autophagy. Cell Chem. Biol. 24, 471-80.
HEK 293T Cerda-Opazo, P., et al. (2018) Inverse expression of survivin and reprimo correlates with poor patient prognosis in gastric cancer. Oncotarget 9, 12853-67.
HeLa Monson, E.A., et al. (2018) Lipid droplet density alters the early innate immune response to viral infection. PLoS One 13, e0190597.
HeLa Foxler, D.E., et al. (2018) A HIF–LIMD1 negative feedback mechanism mitigates the pro‐tumorigenic effects of hypoxia. EMBO Mol. Med. 10, e8304.
HeLa Jeong, M., et al. (2017) USP8 suppresses death receptor-mediated apoptosis by enhancing FLIPL stability. Oncogene 36, 458-70.
HeLa Heschen, C.L., et al. (2017) NuMA recruits dynein activity to microtubule minus-ends at mitosis. eLife 6, e29328.
HepG2 Qi, Z., et al. (2017) Asiatic acid enhances Nrf2 signaling to protect HepG2 cells from oxidative damage through Akt and ERK activation. Biomed. Pharmacother. 88, 252-9
HepG2 Xu, H., et al. (2018) MicroRNA-122 supports robust innate immunity in hepatocytes by suppressing STAT3 phosphorylation. bioRχiv doi: http://dx.doi.org/10.1101/250748
Hs578T Oh, S., et al.(2017) Silencing of Glut1 induces chemoresistance via modulation of Akt/GSK-3β/β-catenin/survivin signaling pathway in breast cancer cells. Arch. Biochem. Biophys. 636, 110-22.
Hs578T Onodera, Y., et al. (2018) Arf6-driven cell invasion is intrinsically linked to TRAK1-mediated mitochondrial anterograde trafficking to avoid oxidative catastrophe. Nat. Comm. 9, 2682.
Hu5/KD3 Higashioki, K., et al. (2017) Myogenic differentiation from MYOGENIN-mutated human iPS cells by CRISPR/Cas9. Stem Cells Intl. 9210494
HuH-7 Monson, E.A., et al. (2018) Lipid droplet density alters the early innate immune response to viral infection. PLoS One 13, e0190597.
HuH-7 Xu, H., et al. (2018) MicroRNA-122 supports robust innate immunity in hepatocytes by suppressing STAT3 phosphorylation. bioRχiv doi: http://dx.doi.org/10.1101/250747
HuH-7.5 Eyre, N.S., et al. (2017) Sensitive luminescent reporter viruses reveal appreciable release of hepatitis C virus NS5A protein into the extracellular environment. Virology 507, 20-31.
Human primary cumulus cells Qiao, G., et al. (2017) Deregulation of WNT2/FZD3/β-catenin pathway compromises the estrogen synthesis in cumulus cells from patients with polycystic ovary syndrome. Biochem. Biophys. Res. Comm. 493, 847-54.
Human foreskin fibroblasts Kalser, J., et al. (2017) Differences in growth properties among two human cytomegalovirus glycoprotein O genotypes. Front. Microbiol. 8, 1609.
Human podocytes Fan, Y., et al. (2017) Rtn1a-mediated endoplasmic reticulum stress in podocyte injury and diabetic nephropathy. Sci. Reports 7, 323.
Human pulmonary artery endothelial cells (HPAEC) Nakajima, H., et al. (2017) Flow-dependent endothelial YAP regulation contributes to vessel maintenance. Develop. Cell 40, 523-36.
Human small airway epithelial cells (SAEC)  Mao, P., et al. (2017) MicroRNA-19b mediates lung epithelial-mesenchymal transition via phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase in response to mechanical stretch. Am. J. Resp. Cell Mol. Biol. 56, 11-9.
Human synovial fluid-derived mesenchymal stem cells Liu, W., et al. (2017) IL-1β impedes the chondrogenic differentiation of synovial fluid mesenchymal stem cells in the human temporomandibular joint. Int. J. Mol. Med. 39, 317-26.
Human umbilical vein endothelial cells Wang, J., et al. (2017) NINJ2– A novel regulator of endothelial inflammation and activation. Cell Signal. 35, 231-41. 
ICC Zhu, X., et al. (2017) Osthole induces apoptosis and suppresses proliferation via the PI3K/Akt pathway in intrahepatic cholangiocarcinoma. Int. J. Mol. Med. 40, 1143-51.

iCell® cardiomyocytes

 Hall, A.R., et al. (2018) Visualizing mutation-specific differences in the trafficking-deficient phenotype of Kv11.1 proteins linked to long QT syndrome type 2. Front. Physiol. 9, 284.
iCell® cardiomyocytes
 Fenix, A.M., et al. (2017) Muscle specific stress fibers give rise to sarcomeres and are mechanistically distinct from stress fibers in non-muscle cell. bioRχiv doi: https://doi.org/10.1101/235424.
iCell® cardiomyocytes Taneja, N., et al. (2018) Focal adhesion kinase regulates early steps of myofibrillogenesis in cardiomyocytes. bioRχiv ; doi: http://dx.doi.org/10.1101/261248.
IGROV1 Alam, S., et al. (2017) Altered (neo-) lacto series glycolipid biosynthesis impairs α2-6 sialylation on N-glycoproteins in ovarian cancer cells. Sci. Reports 7, 45367.
Induced hepatocyte-like cells (iHeps) Katayama, H., et al. (2017) Generation of non-viral, transgene-free hepatocyte like cells with piggyBac transposon. Sci. Reports 7, 44498.
INS-1 Spohrer, S., et al. (2017) Functional interplay between the transcription factors USF1 and PDX-1 and protein kinase CK2 in pancreatic β-cells. Sci. Reports 7, 16367
K562 Espadinha, A.-S., et al. (2017) A tyrosine kinase-STAT5-miR21-PDCD4 regulatory axis in chronic and acute myeloid leukemia cells. Oncotarget 8, 76174-88.
MCF-10A Eriksson, M., et al. (2017) The effect of mutant p53 proteins on glycolysis and mitochondrial metabolism. Mol. Cell. Biol. 37, e00328-17.
MCF7 Bruno, W., et al. (2017) Functional analysis of a CDKN2A 5'UTR germline variant associated with pancreatic cancer development. PLoS One 12, e0189123.
MCF7 Onodera, Y., et al. (2018) Arf6-driven cell invasion is intrinsically linked to TRAK1-mediated mitochondrial anterograde trafficking to avoid oxidative catastrophe. Nat. Comm. 9, 2682.
MDA-MB-231 Oh, S., et al. (2017) Silencing of Glut1 induces chemoresistance via modulation of Akt/GSK-3β/β-catenin/survivin signaling pathway in breast cancer cells. Arch. Biochem. Biophys. 636, 110-22.
MDA-MB-231 Onodera, Y., et al. (2018) Arf6-driven cell invasion is intrinsically linked to TRAK1-mediated mitochondrial anterograde trafficking to avoid oxidative catastrophe. Nat. Comm. 9, 2682.
MDA-MB-231 Eriksson, M., et al. (2017) The effect of mutant p53 proteins on glycolysis and mitochondrial metabolism. Mol. Cell. Biol. 37, e00328-17.
MDA-MB-435s Onodera, Y., et al. (2018) Arf6-driven cell invasion is intrinsically linked to TRAK1-mediated mitochondrial anterograde trafficking to avoid oxidative catastrophe. Nat. Comm. 9, 2682.
MDA-MB-436 Onodera, Y., et al. (2018) Arf6-driven cell invasion is intrinsically linked to TRAK1-mediated mitochondrial anterograde trafficking to avoid oxidative catastrophe. Nat. Comm. 9, 2682.
MDA-MB-438 Onodera, Y., et al. (2018) Arf6-driven cell invasion is intrinsically linked to TRAK1-mediated mitochondrial anterograde trafficking to avoid oxidative catastrophe. Nat. Comm. 9, 2682.
MIN6-K8 Zhang, W., et al. (2017) Neuromedin U suppresses glucose-stimulated insulin secretion in pancreatic β cells. Biochem. Biophys. Res. Comm. 493, 677-83.
MIO-M1 Chu-Tan, J.A., et al. (2018) MicroRNA-124 dysregulation is associated with retinal inflammation and photoreceptor death in the degenerating retina. Invest. Ophthalmol. Vis. Sci. 59, 4094-105.
MOE Dean, M., Davis, D.A. and Burdette, J.E. (2017) Activin A stimulates migration of the fallopian tube epithelium, an origin of high-grade serous ovarian cancer, through non-canonical signaling. Cancer Lett. 391, 114-24.
Mouse embryonic fibroblast Campostrini, G., et al. (2017) The expression of the rare caveolin-3 variant T78M alters cardiac ion channels function and membrane excitability. Cardiovasc. Res. 113, 1256-65.
Mouse Oligodendrocyte progenitor cells (mOPC) Weider, M., et al. (2018) Nfat/calcineurin signaling promotes oligodendrocyte differentiation and myelination by transcription factor network tuning. Nat. Comm. 9, 899.
MRC4V1 Bertoletti, F., et al. (2017) Phosphorylation regulates human polη stability and damage bypass throughout the cell cycle. Nucl. Acids Res. 45, 9441-54.
Murine neural stem cells Bansod, S., Kageyama, R., and Ohtsuka, T. (2017) Hes5 regulates the transition timing of neurogenesis and gliogenesis in mammalian neocortical development. Development 144, 3156-67.
Murine renal tubular epithelial cells Yuan, X., et al. (2017) Bone mesenchymal stem cells ameliorate ischemia/reperfusion-induced damage in renal epithelial cells via microRNA-223. Stem Cell Res. Ther. 8, 146
NCCIT Park, S.-W., et al. (2017) NANOG gene expression is regulated by the ETS transcription factor ETV4 in human embryonic carcinoma NCCIT cells. Biochem. Biophys. Res. Comm.487, 532-8.
NCI-N87 Cerda-Opazo, P., et al. (2018) Inverse expression of survivin and reprimo correlates with poor patient prognosis in gastric cancer. Oncotarget 9, 12853-67.
NIH 3T3 Bansod, S., Kageyama, R., and Ohtsuka, T. (2017) Hes5 regulates the transition timing of neurogenesis and gliogenesis in mammalian neocortical development. Development 144, 3156-67.
NIT-1 Lee, J.-J., et al. (2017) Calcium ion induced structural changes promote dimerization of secretagogin, which is required for its insulin secretory function. Sci. Reports 7, 6976.
NMuMG Morita, T. and Hayashi, K. (2018) Tumor progression is mediated by thymosin-β4 through a TGFβ/MRTF signaling axis. Mol. Cancer Res. 16, 880-93.
NOZ Ma, Q., et al. (2018) EMP3, which is regulated by miR-663a, suppresses gallbladder cancer progression via interference with the MAPK/ERK pathway. Cancer Lett. 430, 97-108.
NOZ Hao, J., et al. (2017) Downregulation of BRD4 inhibits gallbladder cancer proliferation and metastasis and induces apoptosis via PI3K/AKT pathway. Int. J. Oncol. 51, 823-31
OCUG Ma, Q., et al. (2018) EMP3, which is regulated by miR-663a, suppresses gallbladder cancer progression via interference with the MAPK/ERK pathway. Cancer Lett. 430, 97-108.
OCUG Hao, J., et al. (2017) Downregulation of BRD4 inhibits gallbladder cancer proliferation and metastasis and induces apoptosis via PI3K/AKT pathway. Int. J. Oncol. 51, 823-35
PANC1 Villarino, N., et al. (2017) A screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer. Oncotarget 8, 53154-67.
PBMC Cai, F., et al. (2018) MicroRNA-146b-3p regulates the development and progression of cerebral infarction with diabetes through RAF1/P38MAPK/COX-2 signaling pathway. Am. J. Transl. Res. 10, 618-28.
PC3 Xu, H., et al. (2018) MicroRNA-122 supports robust innate immunity in hepatocytes by suppressing STAT3 phosphorylation. bioRχiv doi: http://dx.doi.org/10.1101/250746
PtK2 Long, A.F., Udy, D.B., and Dumont, S. (2017) Hec1 tail phosphorylation differentially regulates mammalian kinetochore coupling to polymerizing and depolymerizing microtubules. Curr. Biol. 27, 1692-9.
PtK2 Heschen, C.L., et al. (2017) NuMA recruits dynein activity to microtubule minus-ends at mitosis. eLife 6, e29328.
RAW264.7 Ricci, E., et al. (2017) Role of the glucocorticoid-induced leucine zipper gene in dexamethasone-induced inhibition of mouse neutrophil migration via control of annexin A1 expression. FASEB J. 31, 3054-65.
RMC Gao, H.-Y. and Han, C.-X. (2017) The role of PTEN up-regulation in suppressing glomerular mesangial cells proliferation and nephritis pathogenesis. Eur. Rev. Med. Pharmacol. Sci. 21, 3634-41.
RPE1 Heschen, C.L., et al. (2017) NuMA recruits dynein activity to microtubule minus-ends at mitosis. eLife 6, e29328.
SaOS2 Nishita, M., et al. (2017) Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness. Sci. Reports 7, 1.
SGC-996 Ma, Q., et al. (2018) EMP3, which is regulated by miR-663a, suppresses gallbladder cancer progression via interference with the MAPK/ERK pathway. Cancer Lett. 430, 97-108.
SGC-996 Hao, J., et al. (2017) Downregulation of BRD4 inhibits gallbladder cancer proliferation and metastasis and induces apoptosis via PI3K/AKT pathway. Int. J. Oncol. 51, 823-34
SH-SY5Y Zhang, Y., et al. (2017) Rescue of Pink1 deficiency by stress-dependent activation of autophagy. Cell Chem. Biol. 24, 471-80.
SK-BR-3 Onodera, Y., et al. (2018) Arf6-driven cell invasion is intrinsically linked to TRAK1-mediated mitochondrial anterograde trafficking to avoid oxidative catastrophe. Nat. Comm. 9, 2682.
SK-HEP-1 McDonald, C.J., et al. (2018) Evaluation of a bone morphogenetic protein 6 variant as a cause of iron loading. Hum. Genom. 12, 23.
SKOV3 Yan, X.-Y., et al. (2017) p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-κB pathway in human ovarian cancer cells. Cancer Sci. 108, 1405-13.
SKOV3 Lu, T., et al. (2018) Blockade of ONECUT2 expression in ovarian cancer inhibited tumor cell proliferation, migration, invasion and angiogenesis. Cancer Sci. 109, 2221-34.
SKOV3 Alam, S., et al. (2017) Altered (neo-) lacto series glycolipid biosynthesis impairs α2-6 sialylation on N-glycoproteins in ovarian cancer cells. Sci. Reports 7, 45367.
SNU-1 Cerda-Opazo, P., et al. (2018) Inverse expression of survivin and reprimo correlates with poor patient prognosis in gastric cancer. Oncotarget 9, 12853-67
SW480 Lin, H., et al. (2017) DHX32 promotes angiogenesis in colorectal cancer through augmenting β-catenin signaling to induce expression of VEGFA. EBioMedicine 18, 62-72
SW620 Lin, H., et al. (2017) DHX32 promotes angiogenesis in colorectal cancer through augmenting β-catenin signaling to induce expression of VEGFA. EBioMedicine 18, 62-72
THP-1 Wiśnik, E.,  Płoszaj, T. and Robaszkiewicz, A. (2017) Downregulation of PARP1 transcription by promoter-associated E2F4-RBL2-HDAC1-BRM complex contributes to repression of pluripotency stem cell factors in human monocytes. Sci. Reports 7, 9483.
TT Jang, S., et al. (2017) Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth in vivo. Oncotarget 8, 70828-40.
U2OS Foxler, D.E., et al. (2018) A HIF–LIMD1 negative feedback mechanism mitigates the pro‐tumorigenic effects of hypoxia. EMBO Mol. Med. 10, e8304.
U2OS Nishita, M., et al. (2017) Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness. Sci. Reports 7, 1.
U373MG Kwon, R.-J., et al.(2017) Roles of zinc-fingers and homeoboxes 1 during the proliferation, migration, and invasion of glioblastoma cells. Tumor Biol. 39, 1010428317694575.
U87 Diplas, B.H., et al. (2018) The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nat. Comm. 9, 2087.
UACC-62 Jeong, M., et al. (2017) USP8 suppresses death receptor-mediated apoptosis by enhancing FLIPL stability. Oncogene 36, 458-70.
WI-38 Eriksson, M., et al. (2017) The effect of mutant p53 proteins on glycolysis and mitochondrial metabolism. Mol. Cell. Biol. 37, e00328-17.

Create Assays Not Possible With Other Reagents


Assay for cytokine signaling in a hematopoietic cell model.

TF-1 suspension cells were transiently transfected with pGL4.32[luc2P/NF-κB-RE/Hygro] Vector, an NF- κB response element luciferase reporter, using either ViaFect™ Transfection Reagent at a 2:1 reagent:DNA ratio or Amaxa Nucleofector® II (electroporation). The following day cells were stimulated with TNFα for 6 hours, and the response was measured with Bio-Glo™ Luciferase Reagent.

TF-1 cells transfected with viafect reagent 12105MB-W

Directly assay HIF1α protein stability in iPS-derived cardiomyocytes.

iCell® Cardiomyocytes (Cellular Dynamics) were transfected with ViaFect™ Transfection Reagent using pNLF1-HIF1A [CMV/neo] Vector, a HIF1A-NanoLuc® Luciferase fusion reporter, at a 4:1 reagent:DNA ratio. Twenty-four hours post-transfection cells were treated as indicated with hypoxia mimetics for 3 hours, and the amount of HIF1α-NanoLuc® protein was detected using Nano-Glo™ Luciferase Assay Reagent.

iPS Cardiomyocytes transfected with viafect 12106MB-W

Assay for hypoxia transcriptional response in iPS-derived cardiomyocytes.

 iCell® Cardiomyocytes (Cellular Dynamics) were transfected with ViaFect™ Transfection Reagent using the pGL4.42[luc2P/HRE/Hygro] Vector, a hypoxia response element luciferase reporter, at a 4:1 reagent:DNA ratio. Twenty-four hours post-transfection, cells were treated with hypoxia mimetics as indicated for 6 hours followed by luciferase detection using ONE-Glo™ Luciferase Assay System. 

cardiomyocyte transfection with viafect reagent 12107MB-W

Protocols

Complete Protocol

Quick Protocols

Specifications

You are viewing: E4981 Change Configuration

What's in the box?

Item Part # Size

ViaFect™ Transfection Reagent

 E498A 1 × 0.75ml

SDS

Search for SDS

Certificate of Analysis

Search by lot number

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

CC

Do not freeze.

Patents and Disclaimers

ViaFect™ Transfection Reagent is sold with a Limited Use Label License.

BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE LABEL LICENSE. If researcher is not willing to accept the terms of this label license, and the product is unused, Promega will accept return of the unused product and provide researcher with a full refund.
Researchers may use this product for research use only and in accordance with all applicable laws, rules and regulations. Researchers shall have no right to reverse engineer this product. With respect to any uses outside this label license, including any diagnostic, therapeutic or prophylactic uses, please contact Promega for supply and licensing information. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THE PRODUCT. The terms of this label license shall be governed under the laws of the State of Wisconsin, USA.

Specifications

You are viewing: E4982 Change Configuration

What's in the box?

Item Part # Size

ViaFect™ Transfection Reagent

 E498A 2 × 0.75ml

SDS

Search for SDS

Certificate of Analysis

Search by lot number

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

CC

Do not freeze.

Patents and Disclaimers

ViaFect™ Transfection Reagent is sold with a Limited Use Label License.

BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE LABEL LICENSE. If researcher is not willing to accept the terms of this label license, and the product is unused, Promega will accept return of the unused product and provide researcher with a full refund.
Researchers may use this product for research use only and in accordance with all applicable laws, rules and regulations. Researchers shall have no right to reverse engineer this product. With respect to any uses outside this label license, including any diagnostic, therapeutic or prophylactic uses, please contact Promega for supply and licensing information. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THE PRODUCT. The terms of this label license shall be governed under the laws of the State of Wisconsin, USA.

Resources

Articles

Citations

Other Resources

Similar Products

FuGENE® HD Transfection Reagent

Enhanced performance in a range of cell types, including difficult-to-transfect cell lines.

E2311, E2312

FuGENE® 6 Transfection Reagent

Proven, dependable performance. Best for everyday use with common cell lines.

E2691, E2692, E2693

ProFection® Mammalian Transfection System

Calcium phosphate-based method for stable or transient transfection of eukaryotic cells.

E1200

FuGENE® SI Transfection Reagent

Innovative transfection reagent for the delivery of siRNA, miRNA and other small RNA molecules into a wide range of eukaryotic cell lines.

E9311, E9312

Frequently Used With

PureYield™ Plasmid Miniprep System

Up to 15μg transfection-ready plasmid from 3ml cultures in 10 minutes.

A1223, A1222

PureYield™ Plasmid Midiprep System

Up to 200µg of transfection-ready plasmid from 50ml cultures in 30 minutes.

A2492, A2495, A2496

Nano-Glo® Dual-Luciferase Reporter Assay System

Ultra-sensitive detection of firefly and NanoLuc® luciferase activities in a single sample.

N1610, N1620, N1630, N1650, N1521, N1531, N1541, N1551

ONE-Glo™ EX Luciferase Assay System

Improved ONE-Glo™ Assay suitable for most firefly applications. Longer lasting signal than original ONE-Glo™ Assay, with increased stability for flexible use and storage.

E8110, E8120, E8130, E8150

Let's find the product that meets your needs.

Talk to a Scientist

Luca

Luca

Italy
Choose your country

Americas

Brazil
/
Canada
/
United States
/

Pacific Asia

Australia
China
/
India
Japan
/
Korea, Republic of
/
Singapore

Europe

Austria
/
Belgium
Denmark
(Incl. Faroe Isl. & Greenland)
Estonia
Finland
(Incl. Åland)
France
/
Germany
/
Iceland
Ireland
Italy
/
Luxembourg
Netherlands
Norway
(Incl. Svalbard)
Poland
/
Spain
/
Sweden
Switzerland
United Kingdom

Manage Cookies

Necessary Cookies

We use these cookies to ensure our site functions securely and properly; they are necessary for our services to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as logging in, using a shopping cart or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of our services will not work without them. Like the other cookies we use, strictly necessary cookies may be either first-party cookies or third - party cookies.

Preference Cookies

We use these cookies to remember your settings and preferences. For example, we may use these cookies to remember your language preferences.

Performance/Statistics Cookies

We use these cookies to collect information about how you interact with our services and to help us measure and improve them. For example, we may use these cookies to determine if you have interacted with a certain page.

Marketing Cookies

We and our advertising partners use these cookies to deliver advertisements, to make them more relevant and meaningful to you, and to track the efficiency of our advertising campaigns, both on our services and on other websites and social media.

Your Privacy Choices

Our website supports your privacy choices by allowing users in select regions to opt out of specific types of sharing/sales/use of cookies and technologies for Targeted Advertising. Visit our Privacy Policy and Cookie Policy pages to learn more about these topics.

Targeted Advertising

Deselect this checkbox to disable cookies related to targeted advertising in your Promega experience. These advertising cookies will no longer be set for this browser and device.

Note: These settings are based on necessary cookies that are placed on your device, and if those cookies are cleared or you access the website from another browser or device, advertising cookies might be reset by default in the future, from which you can opt-out.